118 related articles for article (PubMed ID: 3777961)
1. [Intraperitoneal cavity injection of OK-432 with fresh human serum in a case of carcinomatous peritonitis--determination on the complement-derived chemotactic factor].
Kato H; Kondo Y; Tanigawa M; Kin R; Sugino S; Kondo M
Gan To Kagaku Ryoho; 1986 Oct; 13(11):3251-5. PubMed ID: 3777961
[TBL] [Abstract][Full Text] [Related]
2. New approach to management of malignant ascites with streptococcal preparation OK-432. III. OK-432 attracts natural killer cells through a chemotactic factor released from activated neutrophils.
Hayashi Y; Torisu M
Surgery; 1990 Jan; 107(1):74-84. PubMed ID: 2404351
[TBL] [Abstract][Full Text] [Related]
3. Treatment of cancer ascites by intraperitoneal administration of a streptococcal preparation OK-432 with fresh human complement--role of complement-derived chemotactic factor to neutrophils.
Kondo M; Kato H; Yoshikawa T; Sugino S
Int J Immunopharmacol; 1986; 8(7):715-21. PubMed ID: 3536766
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous intraperitoneal administration of OK-432 and serum enhances superoxide generation from migrated polymorphonuclear leukocytes, with special emphasis on the role of complements.
Yoshikawa T; Takano H; Yoshida N; Kondo M
Immunopharmacol Immunotoxicol; 1995 May; 17(2):265-82. PubMed ID: 7650290
[TBL] [Abstract][Full Text] [Related]
5. [A case of advanced gastric cancer responsive to intratumoral OK-432 injection].
Sakai Y; Maeda M; Koyama W; Totsuka S; Sakamoto S; Kanayama M
Gan To Kagaku Ryoho; 1988 Jun; 15(6):1978-80. PubMed ID: 3382244
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil-mediated tumor cell destruction in cancer ascites. II. A OK-432 attracts killer neutrophils through activation of complement C5.
Fujimura T; Torisu M
Clin Immunol Immunopathol; 1987 May; 43(2):174-84. PubMed ID: 3105938
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of polymorphonuclear leukocytes accumulation examined using inhibitors of complement and arachidonic acid cascade in rats treated with OK-432.
Kato H; Inoue M; Yamamura Y; Tanigawa M; Sano H; Sugino S; Kondo M
Nat Immun Cell Growth Regul; 1989; 8(5):290-300. PubMed ID: 2512482
[TBL] [Abstract][Full Text] [Related]
8. [Management of malignant ascites by intraperitoneal injection of OK-432. Possible mechanism of the reduction of original tumor mass volume].
Katano M; Mizoguchi T; Yamamoto H; Hisatsugu T; Torisu M
Nihon Geka Gakkai Zasshi; 1987 Dec; 88(12):1676-83. PubMed ID: 3447033
[TBL] [Abstract][Full Text] [Related]
9. [Antitumor effect of intraperitoneal administration of a streptococcal preparation, OK-432, in carcinomatous peritonitis. I. Experimental study in the rat].
Saji S; Miya K; Oshita H; Nonomura O; Yokoyama Y; Yamamoto S; Takekoshi T; Sakata K
Gan To Kagaku Ryoho; 1982 Nov; 9(11):1961-8. PubMed ID: 7184383
[TBL] [Abstract][Full Text] [Related]
10. Generation of a complement-derived chemotactic factor for tumor cells in experimentally induced peritoneal exudates and its effect on the local metastasis of circulating tumor cells.
Orr FW; Mokashi S; Delikatny J
Am J Pathol; 1982 Jul; 108(1):112-8. PubMed ID: 7091299
[TBL] [Abstract][Full Text] [Related]
11. Acute inflammation in peritoneal dialysis: experimental studies in rats. Characterization of regulatory mechanisms.
Bazargani F
Swed Dent J Suppl; 2005; (171):1-57, i. PubMed ID: 15847249
[TBL] [Abstract][Full Text] [Related]
12. Intraperitoneal administration of the biological response modifier OK-432 and peritoneal recurrence following gastrectomy.
Tsujitani S; Abe Y; Korenaga D; Saitoh A; Watanabe A; Sugimachi K
Hepatogastroenterology; 1990 Oct; 37(5):498-502. PubMed ID: 2253926
[TBL] [Abstract][Full Text] [Related]
13. [Induction of LAK cells in peritoneal cavity of mice after ip injection of OK-432 and antitumor effect of these LAK cells].
Ishida N; Saito M; Nanjo M
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2681-90. PubMed ID: 6508321
[TBL] [Abstract][Full Text] [Related]
14. [Endoscopic administration of OK-432 in gastric cancer].
Inbe A; Sumii K; Haruma K; Uemura N; Tari A; Yoshihara M; Tokutomi T; Inaba Y; Sekito M; Ogoshi H
Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 1):514-9. PubMed ID: 3954375
[TBL] [Abstract][Full Text] [Related]
15. Locoregional immunotherapy of malignant ascites by intraperitoneal administration of OK-432 plus IL-2 in gastric cancer patients.
Yamaguchi Y; Satoh Y; Miyahara E; Noma K; Funakoshi M; Takashima I; Sawamura A; Toge T
Anticancer Res; 1995; 15(5B):2201-6. PubMed ID: 8572625
[TBL] [Abstract][Full Text] [Related]
16. [Prevention of peritoneal recurrence by combined intra-peritoneal and intra-tumoral injections of OK-432].
Baba H; Tsujitani S; Korenaga D; Kakeji Y; Haraguchi M; Konoe S; Maehara Y; Sugimachi K
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 2):1596-9. PubMed ID: 2389954
[TBL] [Abstract][Full Text] [Related]
17. [Clinical studies on locoregional immunochemotherapy of peritonitis carcinomatosa].
Sugiyama Y; Saji S; Furuta T; Azuma S; Miya K; Umemoto T; Takao H; Kato M; Kanno A
Gan To Kagaku Ryoho; 1992 Aug; 19(10 Suppl):1724-7. PubMed ID: 1530341
[TBL] [Abstract][Full Text] [Related]
18. Neutrophil-mediated tumor cell destruction in cancer ascites.
Katano M; Torisu M
Cancer; 1982 Jul; 50(1):62-8. PubMed ID: 7083126
[TBL] [Abstract][Full Text] [Related]
19. [Endoscopic preoperative intralesional injection of OK-432 in early gastric cancer].
Yamane T; Sagara Y; Suzuki G; Kasuga M; Sakita M; Fujita Y; Majima S
Gan To Kagaku Ryoho; 1984 Apr; 11(4):930-4. PubMed ID: 6721507
[TBL] [Abstract][Full Text] [Related]
20. [A case of recurrence of gastric cancer with an abdominal wall tumor responding to intratumoral OK-432 administration].
Saeki T; Kuninobu H; Niimoto M; Hattori T; Ohoya M; Yoshida H; Sata H; Kajitani Y
Gan No Rinsho; 1987 Apr; 33(4):417-20. PubMed ID: 2952818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
